Temporal Window and Episodic Future Thinking in CUD

Test Reinforcer Pathology Via Manipulation of the Temporal Window With Successive Episodic Future Thinking Generation.

The primary objective is to test the theory of Reinforcer Pathology via manipulation of the temporal window with successive Episodic Future Thinking generation in individuals with cocaine use disorder.

Study Overview

Detailed Description

Adults with cocaine use disorder will be randomly assigned to experimental or control groups, stratified by polydrug use disorder, SES, and sex. The experimental group will compare episodic future thinking (EFT) to control episodic thinking (CET). The study procedures will include a baseline session (S1) and a 4-week intervention period where participants will return to the lab three times a week. Participants will generate new EFT and CET events at approximately weekly intervals. The EFT or CET events will be texted to them twice daily with urine samples obtained thrice-weekly. To probe resistance to disruption, both groups will receive stress-inducing probes that shorten the temporal window after the first and last cue generation. During the first assessment visit (S2), participants will be randomized with stratification to generate either episodic future thinking (EFT) or control episodic thinking (CET) events and will undergo neuroimaging procedures. At the following session in S3, participants will be randomized to receive one of two stress probes (counterbalanced) or their respective control. Participants will be exposed to a stress probe or control at S3 and the corresponding narrative at the next visit, S4. S5 and S6 will begin with participants generating new EFT/CET events that will be used for that session and the following two sessions. S7, like S2, will begin with EFT/CET event generation and neuroimaging procedures. During the final two sessions (S8, S9), participants will be exposed to the other stress probe and control that they did not see during S3/S4.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Kirstin Gatchalian
  • Phone Number: 540-526-2071
  • Email: kmgatch@vt.edu

Study Locations

    • Virginia
      • Roanoke, Virginia, United States, 24016
        • Recruiting
        • Fralin Biomedical Research Institute at VTC
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. demonstrate recent cocaine use and CUD (use in last month, DSM-5 for CUD > 4)
  2. be 18 years of age or older
  3. have a desire to quit or cut down on their cocaine use, but do not have proximate plans to enroll in treatment for CUD during the study period

Exclusion Criteria:

  1. meeting moderate to severe DSM-5 criteria for opioid use disorder
  2. having a current diagnosis of any psychotic disorder
  3. having a history of seizure disorders or traumatic brain injury
  4. having any contraindication for participation in the MRI sessions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Episodic Future Thinking (EFT)
Participants will generate positive future events they are looking forward to at several time points in the future (e.g., 2 weeks, 1 month, 3 months, 1 year, and 5 years). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
Participants will generate descriptions of vivid positive future events.
Other Names:
  • EFT
Sham Comparator: Control Episodic Thinking (CET)
Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). Participants will be reminded of these events using cues throughout the study and instructed to think about these cues as they make their decisions. This intervention will be tested in both the presence and absence of stress probes.
Participants will generate descriptions of vivid positive future events.
Other Names:
  • CET

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Delay Discounting
Time Frame: Over four-weeks of participation (Weekly for four weeks)
Delay discounting tasks provide a measure of the temporal window and examine the devaluation of awards as a function of the delay to the receipt. These computerized assessments provide participants with hypothetical choices between smaller amounts of a reward available immediately and a larger amount of a reward after a range of delays (1 day-25 years). Discounting rates will be measured using adjusting amount delay discounting and minute delay discounting tasks. Change in discounting rates will be compared within-subjects across sessions and between groups.
Over four-weeks of participation (Weekly for four weeks)
Change in Cocaine Demand
Time Frame: Over four weeks of participation (Weekly for four weeks)
Intensity and elasticity of cocaine demand will be determined from a cocaine demand curve via a Cocaine Purchase Task (CPT). Change in cocaine demand will be compared within-subjects across sessions and between groups.
Over four weeks of participation (Weekly for four weeks)
Cocaine Craving
Time Frame: Over four weeks of participation (Weekly for four weeks)
The Desires for Drug Questionnaire (DDQ) will be used to assess instant craving for cocaine. Change in cocaine craving will be compared within-subjects across sessions and between groups.
Over four weeks of participation (Weekly for four weeks)
Neural activation during fMRI delay discounting task
Time Frame: Over four weeks of participation (Baseline, Week 1, Week 4)
Brain maps will be compared between groups and time points.
Over four weeks of participation (Baseline, Week 1, Week 4)
Neural activation during fMRI cocaine purchase task
Time Frame: Over four weeks of participation (Baseline, Week 1, Week 4)
Brain maps will be compared between groups and time points.
Over four weeks of participation (Baseline, Week 1, Week 4)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Daily Cocaine Use
Time Frame: Over four weeks of participation
Daily cocaine use will be assessed via the daily Ecological Momentary Assessments (EMAs). Change in daily cocaine use will be compared within-subjects across the study duration and between groups.
Over four weeks of participation
Cocaine Urinalysis
Time Frame: Over four weeks of participation
Cocaine urinalysis will be measured from the urinalysis collected at sessions and retention check-ins. Change in cocaine urinalysis will be compared within-subjects across the study duration and between groups.
Over four weeks of participation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Warren K Bickel, PhD, Virginia Polytechnic and State University
  • Principal Investigator: Stephen LaConte, PhD, Virginia Polytechnic and State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2022

Primary Completion (Estimated)

March 31, 2025

Study Completion (Estimated)

March 31, 2025

Study Registration Dates

First Submitted

August 5, 2022

First Submitted That Met QC Criteria

August 16, 2022

First Posted (Actual)

August 19, 2022

Study Record Updates

Last Update Posted (Actual)

April 12, 2024

Last Update Submitted That Met QC Criteria

April 11, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • VT IRB #22-529

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cocaine Use Disorder

Clinical Trials on Episodic Future Thinking (EFT)

3
Subscribe